Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Xeris Biopharma Holdings's annualizedNet Income for the quarter that ended in Mar. 2026 was €7.7 Mil. Xeris Biopharma Holdings's average total tangible assets for the quarter that ended in Mar. 2026 was €239.1 Mil. Therefore, Xeris Biopharma Holdings's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 3.23%.
The historical rank and industry rank for Xeris Biopharma Holdings's Return-on-Tangible-Asset or its related term are showing as below:
FRA:2B30'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -109.67 Med: -60.78 Max: 4.89
Current: 4.89
During the past 10 years, Xeris Biopharma Holdings's highest Return-on-Tangible-Asset was 4.89%. The lowest was -109.67%. And the median was -60.78%.
FRA:2B30's Return-on-Tangible-Asset is ranked better than 58.37% of 1009
companies
in the Drug Manufacturers industry
Industry Median: 3.08
vs FRA:2B30: 4.89
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Xeris Biopharma Holdings Return-on-Tangible-Asset Related Terms
Xeris Biopharma Holdings Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Xeris Biopharma Holdings's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2B30 vs HROW, PRGO, PAHC: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Xeris Biopharma Holdings's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xeris Biopharma Holdings Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Xeris Biopharma Holdings's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Xeris Biopharma Holdings's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 3.23% mean?
Xeris Biopharma Holdings (FRA:2B30) has a Return-on-Tangible-Asset of 3.23% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Xeris Biopharma Holdings and its competitors. According to the industry distribution chart, Xeris Biopharma Holdings ranks #420 out of 1009 companies in the Drug Manufacturers industry, placing it in the top 41.6%.
Is Xeris Biopharma Holdings' Return-on-Tangible-Asset too high?
Xeris Biopharma Holdings' current Return-on-Tangible-Asset is 3.23%. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.08. Xeris Biopharma Holdings' value of 3.23% is 4.9% above this industry median. Based on the distribution chart, Xeris Biopharma Holdings ranks #420 out of 1009 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Xeris Biopharma Holdings has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xeris Biopharma Holdings' Return-on-Tangible-Asset compare to HROW and PRGO?
According to the Drug Manufacturers industry distribution chart, Xeris Biopharma Holdings ranks #420 out of 1009 companies for Return-on-Tangible-Asset. This puts Xeris Biopharma Holdings in the upper half of its industry. The industry median Return-on-Tangible-Asset is 3.08. Xeris Biopharma Holdings' value of 3.23% is 4.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.08, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xeris Biopharma Holdings's current Return-on-Tangible-Asset of 3.23% is 4.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Xeris Biopharma Holdings and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xeris Biopharma Holdings's current Return-on-Tangible-Asset is 3.23%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xeris Biopharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Xeris Biopharma Holdings (FRA:2B30) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.48, compared to a current price of €6.89 — trading 53.8% above its estimated fair value. The current Return-on-Tangible-Asset is 3.23% and 4.9% above the Drug Manufacturers industry median of 3.08. Xeris Biopharma Holdings' overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Xeris Biopharma Holdings (FRA:2B30), the current Return-on-Tangible-Asset is 3.23% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xeris Biopharma Holdings (FRA:2B30) Overvalued in 2026?
Based on GuruFocus' analysis, Xeris Biopharma Holdings stock appears to be overvalued.
The current stock price of €6.89 is trading 53.8% above its estimated GF Value™ of €4.48.
GuruFocus considers Xeris Biopharma Holdings to be Significantly Overvalued.
Key valuation signals for FRA:2B30:
Return-on-Tangible-Asset: 3.23%
GF Value™: €4.48 vs. price of €6.89 (53.8% above fair value)
Industry Position: 4.9% above the Drug Manufacturers median (#420 of 1009)
No single metric tells the full story. See the FRA:2B30 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
74GF Score
Get the complete analysis for FRA:2B30
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2B30 has been successfully added to your 
